Bruker Expands Microbiology Portfolio with FDA-Cleared Enhancements and Rapid AST Innovations — Bruker Corporation

Event summary

Bruker's Microbiology & Infection Diagnostics division showcased expanded portfolio at ASM Microbe 2026, including FDA Claims 7 and 8 for MALDI Biotyper® CA System.
New solutions introduced for MALDI Biotyper RUO/GP systems, including MBT Easy T® Kit and expanded library covering 5,325 species.
Bruker highlighted rapid antimicrobial susceptibility testing (AST) workflow under development for sepsis diagnostics.
MBioSEQ® Ridom Typer software (RUO) introduced for reflex NGS testing, integrating with MALDI Biotyper and IR Biotyper workflows.
Bruker reported 140 new system placements in 2025 and double-digit consumables growth, with continued momentum into 2026.

The big picture

Bruker's expansions at ASM Microbe 2026 reflect the growing demand for rapid, actionable diagnostics in clinical microbiology, particularly for sepsis and bloodstream infections. The company's focus on integrating advanced technologies like NGS and MALDI-TOF mass spectrometry positions it to capitalize on the shift toward faster, more precise diagnostic workflows. The continued regulatory approvals and market growth underscore Bruker's strategic push to dominate the infection diagnostics space.

What we're watching

Regulatory Approvals: The pace at which Bruker secures additional FDA clearances for its microbial identification and AST solutions will determine the speed of market adoption.
Market Penetration: Whether Bruker can sustain its double-digit growth in system placements and consumables, particularly in the U.S. market.
Technological Integration: How effectively Bruker integrates its MALDI Biotyper, IR Biotyper, and MBioSEQ Ridom Typer workflows to provide comprehensive diagnostic solutions.